First Light Acquisition Group Announces NYSE Approval For Listing Of Business Combination With Calidi Biotherapeutics And Additional New Capital Commitments
Portfolio Pulse from Benzinga Newsdesk
First Light Acquisition Group has announced that its business combination transaction with Calidi Biotherapeutics has been approved for listing on the NYSE. The transaction, expected to be completed on September 12, 2023, will provide Calidi with approximately $28 million in gross proceeds. Additionally, Calidi has secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP. The listed company will be named Calidi Biotherapeutics, Inc. and will trade under the ticker symbols 'CLDI' and 'CLDI WS'.
September 11, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calidi Biotherapeutics is set to receive approximately $28 million from a business combination transaction with First Light Acquisition Group, and an additional $10 million from a consortium. The company will be listed on the NYSE under the ticker 'CLDI'.
The business combination transaction and additional capital commitments will provide Calidi Biotherapeutics with significant funding, which could be used for further research and development, potentially leading to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100